The backtest results for VALN show mixed performance following earnings beats, with a 50% win rate at both 3 and 10 days, but a 0% win rate at 30 days. Short-term returns are positive, with 1.02% over 3 days and 3.69% over 10 days, yet the 30-day return turns negative at -7.51%. This suggests initial optimism fades over a longer horizon.

The data indicates that while immediate gains are possible, holding VALN beyond 10 days post-earnings beat may carry risk.

Investors might consider short-term trades around earnings beats rather than long-term holds for VALN.

backtest_data

The backtest results show that VALN has a 62.5% win rate at 3 and 30 days post-earnings miss, but the 30-day average return is negative at -0.86%. Short-term returns are near neutral, with a slight positive at 10 days. This indicates mixed price reactions with limited downside but no strong gains following earnings misses.

The data suggests that while VALN often avoids losses shortly after earnings misses, the overall trend leans slightly negative over a month. Investors should be cautious and consider the modest negative return risk when trading VALN after earnings misses.

A defensive or neutral stance may be prudent, avoiding aggressive long positions immediately after earnings misses for VALN.

The backtest results show that the Biotechnology Industry experienced a negligible maximum return of 0.19% on the event day following earnings beats, with an overall negative impact observed across 728 events. This suggests that earnings beats in this sector do not translate into significant positive price movements. The analysis indicates limited market enthusiasm or other overriding factors dampening gains despite positive earnings surprises. Investors should be cautious about expecting strong immediate gains from earnings beats in the Biotechnology Industry and consider other factors before making investment decisions.

The backtest results show that earnings misses in the Biotechnology Industry had no significant impact on stock returns, with a maximum return of only 0.01% observed three days after the event. This indicates that the industry’s stock prices are largely unaffected by earnings misses over the tested period from 2023 to 2026.

The lack of response suggests that investors may have already priced in earnings misses or that other factors dominate stock performance in this sector.

For investors, this implies limited trading opportunities based solely on earnings misses within the Biotechnology Industry.

Backtest VALN Release Earning Report

Find all upcoming company earnings reports scheduled for mar 01 2026. Get details on which companies are reporting and their expected results.

Calendar